ArticleJournal of cosmetic dermatology2026
Translating Geroscience Into Clinical Longevity Dermatology: From Mechanisms of Aging to Skin-Centered Interventions.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLongevity medicine is an emerging clinical framework aimed at extending healthspan by targeting the biological mechanisms of aging rather than treating disease in isolation. Geroscience, which investigates the molecular and cellular pathways linking aging to chronic pathology, provides the scientific foundation for this approach. Dermatology is uniquely positioned within this paradigm, as the skin represents both a visible marker of biological aging and an accessible source of biomarkers.
objectiveTo explore how principles of geroscience can be translated into clinical dermatology and cosmetic practice, with a focus on skin-centered biomarkers, artificial intelligence (AI), and preventive longevity-oriented interventions.
methodsThis piece integrates current evidence from geroscience, dermatologic aging research, microbiome science, and AI-driven analytics to examine emerging models of longevity-focused dermatologic care. Conceptual frameworks, clinical readiness of interventions, and ethical considerations are critically discussed.
resultsAdvances in biological aging biomarkers, including epigenetic clocks, inflammatory signatures, mitochondrial and metabolic markers, and skin microbiome profiling, offer promising tools for assessing cutaneous and systemic aging. AI-enabled platforms facilitate the integration of multidimensional data, enabling refined biological age assessment and potential prediction of treatment responses. However, most longevity-oriented diagnostics and interventions remain in early or experimental stages, requiring rigorous validation before routine clinical adoption.
conclusionDermatology can serve as a translational bridge between geroscience and clinical longevity medicine by integrating validated skin biomarkers, aesthetic procedures, and preventive strategies within an evidence-based framework. Careful attention to scientific limitations, ethical considerations, and health equity is essential to ensure responsible implementation. Dermatologists would play a key role in shaping clinically sound, prevention-focused longevity care centered on long-term skin health and resilience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.